

Acknowledgement and Consent for Disclosure Document of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

Terry Davis, Ph.D.

Committee: **Drug Safety and Risk Management Advisory Committee**

Meeting Dates: February 9 & 10, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the agenda items (1) discussion of approaches that could be used to study whether Attention Deficit Hyperactivity Disorder (ADHD) products increase the risk of adverse cardiovascular outcomes: and, (2) The Agency's action for the COX – 2 selective Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Stock	A firm that could potentially be affected by the committee's discussions of approaches that could be used to study whether ADHD drugs increase the risk of cardiovascular outcomes.	Valued from \$25,001 to \$50,000
Stock	A firm that could potentially be affected by the committee's discussions of COX-2 selective Nonsteroidal Anti-Inflammatory Drugs.	Valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interests, the waiver is not valid.

Signature of SGE

Date